X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
CLN-978 is a novel, highly potent, half-life extended CD19xCD3 bispecific T cell engager construct. It is being evaluated for autoimmune diseases, with systemic lupus erythematosus as a first indication.
Lead Product(s): CLN-978
Therapeutic Area: Immunology Product Name: CLN-978
Highest Development Status: IND EnablingProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 16, 2024
Details:
The proceeds from the financing will used to support Cullinan’s ongoing research and development activities, and the expansion of its CD19xCD3 T cell engager clinical program including CLN-978 for the treatment of Systemic lupus erythematosus.
Lead Product(s): CLN-978
Therapeutic Area: Immunology Product Name: CLN-978
Highest Development Status: IND EnablingProduct Type: Large molecule
Partner/Sponsor/Collaborator: Adage Capital Partners
Deal Size: $280.0 million Upfront Cash: Undisclosed
Deal Type: Private Placement April 16, 2024
Details:
CLN-619 is a potential first-in-class humanized IgG1 monoclonal antibody that binds to stress-induced ligands, MICA and MICB. It is being evaluated for the treatment of relapsed/refractory multiple myeloma.
Lead Product(s): CLN-619
Therapeutic Area: Oncology Product Name: CLN-619
Highest Development Status: IND EnablingProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 01, 2024
Details:
CLN-617 is a potential cytokine therapy comprised of IL-2 and IL-12 antitumor cytokines, in a single molecule. CLN-617 alone and in combination with pembrolizumab is being evaluated in phase 1 clinical trials for the treatment of patients with advanced solid tumors.
Lead Product(s): CLN-617,Pembrolizumab
Therapeutic Area: Oncology Product Name: CLN-617
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 14, 2023
Details:
CLN-978 is a novel, highly potent, half-life extended CD19/CD3 bispecific T-cell engaging antibody construct. CLN-978 contains two single-chain variable fragments (scFv), one recognizing with high affinity CD19 on malignant cells and the other targeting CD3 on T-cells.
Lead Product(s): CLN-978
Therapeutic Area: Oncology Product Name: CLN-978
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 09, 2023
Details:
CLN-617 is a potential cytokine therapy uniquely combining two potent and synergistic antitumor cytokines, IL-2 and IL-12, in a single molecule. It directs a broad immune response to eradicate the injected tumor as well as distant tumor sites as per preclinical studies.
Lead Product(s): CLN-617,Pembrolizumab
Therapeutic Area: Oncology Product Name: CLN-617
Highest Development Status: IND EnablingProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 27, 2023
Details:
CLN-617 is a potential cytokine therapy uniquely combining two potent and synergistic antitumor cytokines, IL-2 and IL-12, in a single molecule. It directs a broad immune response to eradicate the injected tumor as well as distant tumor sites as per preclinical studies.
Lead Product(s): CLN-617
Therapeutic Area: Oncology Product Name: CLN-617
Highest Development Status: IND EnablingProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 14, 2023
Details:
Under the agreement, Cullinan Oncology will have the exclusive right to develop and commercialize CLN-418/HBM7008 in the U.S. CLN-418/HBM7008 is a B7H4 x 4-1BB bispecific immune activator developed from next-gen HCAb-based multi-specific antibody discovery platform HBICE®.
Lead Product(s): HBM7008
Therapeutic Area: Oncology Product Name: HBM7008
Highest Development Status: Phase IProduct Type: Large molecule
Recipient: Nona Biosciences
Deal Size: $588.0 million Upfront Cash: $25.0 million
Deal Type: Licensing Agreement February 13, 2023
Details:
CLN-978 is a novel, highly potent, half-life extended CD19/CD3 bispecific T-cell engaging antibody construct. CLN-978 contains two single-chain variable fragments (scFv), one recognizing with high affinity CD19 on malignant cells and the other targeting CD3 on T-cells.
Lead Product(s): CLN-978
Therapeutic Area: Oncology Product Name: CLN-978
Highest Development Status: IND EnablingProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 24, 2023
Details:
CLN-619 is a humanized IgG1 monoclonal antibody that binds to MICA and MICB, ligands expressed on a wide variety of hematological and solid tumors that are recognized by both cytotoxic innate and adaptive immune cells via their NKG2D receptors.
Lead Product(s): CLN-619,Pembrolizumab
Therapeutic Area: Oncology Product Name: CLN-619
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 25, 2022
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
